Guilin Pharmaceutical Donates Anti-Malaria Drugs To Accra Psychiatric Hospital
Guilin Pharmaceutical Ghana as part of their social responsibility has donated loads of anti-malaria drugs to the Accra Psychiatric hospital.
The drugs [artesunate for injection] worth Ghc 11, 700 is believed to help wards battle malaria.
During the presentation, the Managing Director of Guilin Pharmaceutical, Mr. Wang Yafeng, pledged to always support the psychiatric hospital and other health sectors across the country.
He noted that Guilin Pharmaceutical has been producing intravenous (IV) artesunate for patients with severe malaria since 1987.
The Chief Psychiatrist and Medical Director of the Accra psychiatric hospital, Dr. Akwasi Osei who received the drugs lauded the company for the kind gesture.
He also called on other companies and philanthropists to come to the aid of the mentally disable wards.
About Guilin Pharmaceutical
Founded in 2008, Guilin Pharmaceutical (Shanghai) Co., Ltd. (GPSC) is a subsidiary of Guilin Pharmaceutical Co., Ltd. as well as a member of Fosun Pharmaceutical Group. Focusing on international market business, we develop, produce and market various kinds of pharmaceutical products, including anti-malarials, and generic pharmaceuticals.
We market our products in developing countries, and supply our products to clients all over the world, such as WHO, UNICEF, ICRC, MSF, as well as other governmental, profit- and non-profit organizations.
Guilin Pharma supplies various pharmaceutical products fulfilling international pharmacopeias such as USP / BP. We manufacture pharmaceutical products in workshops qualified by World Health Organization (WHO) GMP. Our workshops have also been inspected by drug authorities from many countries, as well as quality auditors from profit and non-profit organizations.
At present, Guilin Pharma is building a new manufacturing site which will comply with US cGMP standards and maintain a balanced response to EU cGMP/ WHO GMP. In future, we will have a production capacity of over 15 billion tablets/capsules per year to meet the needs of both domestic and global markets.
<<Print>>